Related Experiment Videos
ZD-0473 AstraZeneca
1Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. m.hay@auckland.ac.nz
Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
Summary
ZD-0473 is a novel platinum (II) complex developed for cisplatin-resistant cancers. Clinical trials are underway for solid tumors, with potential market entry anticipated in 2003.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- ZD-0473, a sterically hindered platinum (II) complex, was designed to overcome cisplatin resistance in cancer treatment.
- Developed by Johnson Matthey Technology and the Cancer Research Campaign (CRC), it is now under AstraZeneca's development.
Purpose of the Study:
- To evaluate ZD-0473 as a potential treatment for cisplatin-resistant cancers, particularly solid tumors.
- To assess the safety, tolerability, and pharmacokinetic profile of ZD-0473 in clinical trials.
Main Methods:
- Intravenous (i.v.) formulation of ZD-0473 entered Phase II clinical trials for solid tumors in December 1999.
- Phase I trials in the US, commencing November 1999, focused on determining maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics.
- Oral formulation is undergoing preclinical development.
Main Results:
- Phase I trials were conducted to establish safety and pharmacokinetic parameters.
- Phase II trials for the i.v. formulation commenced for solid tumor treatment.
- AstraZeneca anticipates filing for registration in Q4 2002.
Conclusions:
- ZD-0473 shows promise as a treatment for cisplatin-resistant cancers.
- Further clinical development and regulatory filings are planned by AstraZeneca.